euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement
/ - Turnover increased to EUR168.4 m after three quarters
- Above-average growth in adjusted result (DVFA/SG), increasing to EUR9.2 m
- Continued expansion in revenue and re
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
9-month report
08.05.2007
Berlin, 8th May 2007. During the first three quarters of the 2006/2007 fiscal year, Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) further enhanced its turnover figures, reporting growth of 7.3% to EUR168.4 m (previous year´s figure: EUR156.9 m). The result according to DVFA/SG (IFRS) rose EUR2.5 m and now stands at EUR9.2 m, up from the previous year´s figure of EUR6.7 m. This represents a result per share in the amount of EUR0.76, compared with EUR0.55 for the same period in the previous year. Unadjusted net income on the year decreased as planned, due to the extraordinary capital gain from the sale-and-leaseback transaction of EUR8.6 m the previous year, putting this year´s figure at EUR2.8 million.
Both revenue and results continued to develop positively in the core segment Care, in which the Marseille clinics represent 83% of the total bed-capacity of the corporation. With EUR123.8 m, Marseille-Kliniken realised EUR5.0 m in turnover growth for this segment for the reporting period, up from EUR118.8 m in turnover for the previous year. Due to added capacities and a rise in capacity utilisation from last year´s level of 91.7% to 92.8% currently, the result improved, growing by EUR0.3 m from EUR10,0 m the previous year to the current level of EUR10.3 m.
The positive trend in the rehabilitation segment is ongoing as well. As a result - and despite a physicians´ strike during the current reporting period - capacity utilisation in this segment rose to 75.8%, up from 74.9% the previous year. This influenced the capacity-utilisation trend throughout the group, where capacity utilisation grew once again, from 88.6% to 89.9%. During the period of reporting, the rehabilitation segment reported EUR37.6 m in turnover, EUR2.3 m more than the previous year´s figure of EUR35.3 m. The result according to DVFA/SG (IFRS), EUR-1.1 m, was markedly higher than the previous year´s result of EUR-3.4 m.
The company brought the slightly weaker third quarter to a positive conclusion, with another increase in its capacity-utilisation rate. This, combined with a sustained series of encouraging developments in the care and rehabilitation areas, prefigure continued growth in turnover and result for the entire Marseille-Kliniken Group during the 2006/2007 financial year.
End of the ad-hoc release
end of announcement euro adhoc 08.05.2007 07:11:46
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin, Germany
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
www.marseille-kliniken.com
Hillermann Consulting
Christian Hillermann
Eppendorfer Baum 5
20249 Hamburg, Germany
Tel.:+49 40 / 414069-13
Fax: +49 40 / 414069-14
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Hamburger Wertpapierbörse / official dealing